Skip to main content
SpringerLink
Log in

Pharmacokinetics and Neuromuscular Blocking Effects of Atracurium Besylate and Two of Its Metabolites in Patients with Normal and Impaired Renal Function

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

The pharmacokinetics of atracurium, laudanosine and the quaternary alcohol were studied in patients with normal and impaired renal function following intravenous administration of atracurium. Anaesthesia consisted of thiopental, fentanyl, halothane and nitrous oxide in oxygen. Plasma and urine concentrations of the parent compound and its degradation products were measured by high performance liquid chromatography. Renal failure was defined as a creatinine clearance of less than 5 ml/min; it caused no significant differences in the pharmacokinetics of atracurium but did result in a different pharmacokinetic profile of laudanosine, with a 3-fold increase in the mean (± SD) terminal half-life (176 ± 84 and 516 ± 262 minutes for patients with normal and impaired renal function, respectively). Moreover, the half-life of the quaternary alcohol increased from 27.1 ± 8.3 minutes in patients with normal renal function to 42.5 ± 8.3 minutes in those with impaired renal function (mean ± SD). Renal elimination of unchanged atracurium accounted for 11% of the administered dose and at least 27% of the total degradation of atracurium occurred via ester hydrolysis.

The neuromuscular function was monitored by measuring the twitch tension of the adductor pollicis muscle elicited by stimulation of the ulnar nerve at 0.1Hz. The total duration of neuromuscular blockade (51.8 ± 11.5 minutes) and the recovery index (9.6 ± 2.0 minutes) are shortened in patients with impaired renal function, compared with those with normal renal function (64.1 ± 7.2 and 16.7 ± 4.1 minutes, respectively), indicating that sensitivity to the neuromuscular blocking action of atracurium may be altered by renal failure.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Babel A. Étude comparative de la laudanosine et de la papavérine au point de vue pharmacodynamique. Revue Médicale de la Suisse Romande 19: 657–688, 1899

    Google Scholar 

  • Bencini AF, Scaf AHJ, Sohn YJ, Meistelman C, Lienhart A. et al. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesthesia and Analgesia 65: 245–251, 1986

    Article  PubMed  CAS  Google Scholar 

  • Boxenbaum AG, Riegelmann S, Elashoff RM. Statistical estimation in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 2: 123–144, 1974

    PubMed  CAS  Google Scholar 

  • Chappie DJ, Miller AA, Wheatley PL. Neurological effects of laudanosine in conscious and anaesthetised dogs. Abstract. Anesthesiology 63: A311, 1985

    Article  Google Scholar 

  • Curtis DR, Duggan AW, Felix D, Johnston GAR. Bicuculline, an antagonist of GABA and synaptic inhibition in the spinal cord of the cat. Brain Research 32: 69–96, 1971

    Article  PubMed  CAS  Google Scholar 

  • De Bros FM, Lai A, Scott R, De Bros J, Batson AG. et al. Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients. Anesthesia and Analgesia 65: 743–746, 1986

    Google Scholar 

  • Fahey MR, Rupp SM, Canfell C, Fisher DM, Miller RD. et al. Effect of renal failure on laudanosine excretion in man. British Journal of Anaesthesia 57: 1049–1051, 1985

    Article  PubMed  CAS  Google Scholar 

  • Fahey MR, Rupp SM, Fisher DM, Miller RD, Sharma M. et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 61: 699–702, 1984

    Article  PubMed  CAS  Google Scholar 

  • Hull CJ. A model for atracurium?. British Journal of Anaesthesia 55: 95–96, 1983

    Article  PubMed  CAS  Google Scholar 

  • Hunter JM, Jones RS, Utting JE. Comparison of vecuronium, atracurium and tubocurarine in normal patients and in patients with no renal function. British Journal of Anaesthesia 56: 941–950, 1984

    Article  PubMed  CAS  Google Scholar 

  • Mercier J, Mercier E. Action de quelques alcaloides secondaires de l’opium sur l’électrocorticogramme du chien. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales 149: 760–762, 1955

    PubMed  CAS  Google Scholar 

  • Neill EAM, Chapple DJ. Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non enzymic inactivation at physiological pH. Xenobiotica 12: 203–210, 1982

    Article  PubMed  CAS  Google Scholar 

  • Nguyen HD, Kaplan R, Nagashima H, Duncalf D, Foldes FF. The neuromuscular effect of atracurium in anephric patients. Abstract. Anesthesiology 63: A335, 1985

    Article  Google Scholar 

  • Nigrovic V, Gallup W, Pandya J, Fry K. Generation of reactive metabolites during spontaneous degradation of atracurium in vitro. American Journal of Medical Sciences 296: 12–17, 1989

    Article  Google Scholar 

  • Nigrovic V, Pandya JB. Reactivity and toxicity of atracurium and its metabolites in vitro. Canadian Journal of Anaesthesia 36: 262–268, 1989

    Article  PubMed  CAS  Google Scholar 

  • Nigrovic V, Smith S. Involvement of nucleophiles in the inactivation of atracurium. British Journal of Anaesthesia 59: 617–621, 1987

    Article  PubMed  CAS  Google Scholar 

  • Parker CJP, Jones JE, Hunter JM. Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. British Journal of Anaesthesia 61: 531–540, 1988

    Article  PubMed  CAS  Google Scholar 

  • Pong SF, Graham LT. A relatively simple differential screening test for GABA or glycine antagonists using rat electroretinography. Archives Internationales de Pharmacodynamie et de Thérapie 220: 275–286, 1976

    PubMed  CAS  Google Scholar 

  • Scaf AHJ. Pharmacokinetic analyses with RUGF1T: an interactive pharmacokinetic computer program. Biopharmaceutics and Drue Disposition 9: 415–446, 1988

    Article  CAS  Google Scholar 

  • Stenlake JB, Waigh RD, Dewar GH, Dhar NC, Hughes R. et al. Biodegradable neuromuscular blocking agents. Stereochemical studies on atracurium and related polyalkylene di-esters. European Journal of Medical Chemistry 19: 441–450, 1984

    CAS  Google Scholar 

  • Stenlake JB, Waigh RD, Urwin J, Dewar GH, Coker GG. Atracurium: conception and inception. British Journal of Anaesthesia 55: 3S–10S, 1983

    Article  PubMed  Google Scholar 

  • Tsui D, Graham DD, Torda TA. The pharmacokinetics of atracurium isomers in vitro and in humans. Anesthesiology 67: 722–728, 1987

    Article  PubMed  CAS  Google Scholar 

  • Uges DRA, Bloemhof H, Agoston S. The determination of atracurium and its metabolite laudanosine in serum by HPLC. Abstract. Pharmaceutisch Weekblad-Scientific Edition 6: 265, 1984

    Article  Google Scholar 

  • Ward S, Boheimer N, Weatherley BC, Simmonds RJ, Dopson TA. Pharmacokinetics of atracurium and its metabolites in patients with normal renal function, and in patients in renal failure. British Journal of Anaesthesia 59: 697–706, 1987

    Article  PubMed  CAS  Google Scholar 

  • Ward S, Neill EAM. Pharmacokinetics of atracurium in acute hepatic failure (with acute renal failure). British Journal of Anaesthesia 55: 1169–1172, 1983

    Article  PubMed  CAS  Google Scholar 

  • Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. British Journal of Anaesthesia 58: 6s–10s, 1986

    Article  PubMed  CAS  Google Scholar 

  • Ward S, Wright D. Combined pharmacokinetic and pharmacodynamic study of a single bolus dose of atracurium. British Journal of Anaesthesia 55: 35S–38S, 1983

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Research Group for Experimental Anesthesiology and Clinical Pharmacology, University of Groningen, Groningen, The Netherlands

    Ron H. G. Vandenbrom, J. Mark K. H. Wierda & Sandor Agoston

Authors
  1. Ron H. G. Vandenbrom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mark K. H. Wierda
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sandor Agoston
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vandenbrom, R.H.G., Wierda, J.M.K.H. & Agoston, S. Pharmacokinetics and Neuromuscular Blocking Effects of Atracurium Besylate and Two of Its Metabolites in Patients with Normal and Impaired Renal Function. Clin Pharmacokinet 19, 230–240 (1990). https://doi.org/10.2165/00003088-199019030-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199019030-00006

Keywords

Search

Navigation